The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Acquisitions have the potential to add at least $1 billion in sales by 2028
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated
